Hengrui Pharmaceutical (600276.SH) launches phase III study on long-acting insulin+GLP-1 analogue compound formulation

On April 28, the drug clinical trial registration and information disclosure platform showed that Hengrui Pharmaceutical (600276.SH) initiated a phase III clinical trial (CTR20241529) of HR17031 injections with randomized, open, parallel control, and treatment compliance.

Zhitong FinanceApr 28 20:42 ET

Hengrui Pharma Gets Nod to Trial Insulin Aspart Injection; Shares Up 3%

Jiangsu Hengrui Pharmaceuticals (SHA:600276) will conduct clinical trials on insulin aspart injection after receiving approval from China's National Medical Products Administration, according to the c

MT NewswiresApr 26 01:15 ET

Why Jiangsu Hengrui Medicine's (SHSE:600276) Earnings Are Better Than They Seem

Despite posting healthy earnings, Jiangsu Hengrui Medicine Co., Ltd.'s (SHSE:600276 ) stock has been quite weak. We have done some analysis, and found some encouraging factors that we believe the sha

Simply Wall StApr 25 19:42 ET

Haitong International: Free circuit with long slopes and heavy snow, domestic market space is expected to open up

The Zhitong Finance App learned that Haitong International released a research report saying that compared with innovative domestic drugs to replace relatively mature oncology drugs, self-exempt drugs also have the advantage of a large market size (suitable for the domestic pricing environment for new drugs). The differences are that patients are widely distributed (channel coverage is required), are more chronic diseases, and there is competition for traditional drugs (requiring fast efficacy and high accessibility). Combined with the current market financing environment, although the self-defense target layout is still crowded, companies with good cash flow will be more likely to obtain excess profits. It is recommended to pay attention to Hengrui Pharmaceutical (600276.SH), Kangzhe Pharmaceutical (00867), Sansheng Guojian (688)

Zhitong FinanceApr 25 09:09 ET

Hengrui Pharmaceutical's 2023 performance rebounded steadily, and the sales expense ratio declined year-on-year

On the evening of April 17, Hengrui Pharmaceutical released its 2023 annual report. In 2023, Hengrui Pharmaceutical achieved operating income of 22.82 billion yuan, up 7.26% year on year, net profit attributable to shareholders of listed companies of 4.302 billion yuan, up 10.14% year on year, deducted non-net profit attributable to shareholders of listed companies of 4.141 billion yuan, up 21.46% year on year, net operating cash flow of 7.644 billion yuan, a sharp increase of 504.12% year on year. According to the report's analysis, as Hengrui Pharmaceutical's innovative achievements continue to be approved, the clinical value of innovative drugs is highlighted, driving revenue growth. 2023

China InvestorsApr 25 04:33 ET

Hengrui Pharmaceutical (600276.SH): Injectable carelizumab obtains drug clinical trial approval notice

Gelonghui, April 22丨Hengrui Pharmaceutical (600276.SH) announced that its subsidiary Suzhou Shengdia Biomedical Co., Ltd. has received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for injectable carelizumab and will conduct clinical trials in the near future. Injectable carelizumab is a humanized anti-PD-1 monoclonal antibody that binds to human PD-1 receptors and blocks the PD-1/PD-L1 pathway to restore the body's anti-tumor immunity, thus forming the basis for cancer immunotherapy.

Gelonghui FinanceApr 22 04:48 ET